plxna3 Antibody

What is PLXNA3 and what are its primary biological functions?

PLXNA3 (Plexin A3) is a transmembrane protein encoded by the PLXNA3 gene, with a molecular weight of approximately 207.7 kDa and 1871 amino acid residues in its canonical form. It is primarily localized in the cell membrane and functions as a member of the Plexin protein family . PLXNA3 serves as a coreceptor for class 3 semaphorins, particularly SEMA3A and SEMA3F, and plays crucial roles in:

• Axon guidance during nervous system development

• Cytoskeletal remodeling following semaphorin signaling

• Regulation of sympathetic neuron migration

• Maintenance of normal dendrite spine morphology in pyramidal neurons

• Cell migration processes with implications in both developmental biology and pathological conditions

Alternative names include plexin-4, semaphorin receptor SEX, and Sex chromosome X transmembrane protein of HGF receptor family 3 .

What types of PLXNA3 antibodies are available for research applications?

PLXNA3 antibodies are available in several formats to accommodate different experimental needs:

Most commercially available PLXNA3 antibodies demonstrate reactivity with human samples, while some also cross-react with mouse and rat orthologs . When selecting an antibody, researchers should consider the specific application requirements and target species, as species cross-reactivity varies between products.

What are the optimal conditions for using PLXNA3 antibodies in Western blot applications?

For successful Western blot detection of PLXNA3, follow these methodological recommendations:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors for cell/tissue lysis

  • Due to PLXNA3's high molecular weight (207.7 kDa), employ lower percentage gels (6-8%) for optimal separation

• Running conditions:

  • Use lower voltage (80-100V) for longer running times to improve separation of high molecular weight proteins

  • Consider gradient gels (4-12%) to maximize resolution

• Transfer parameters:

  • Employ wet transfer systems rather than semi-dry for large proteins

  • Extend transfer time (overnight at 30V at 4°C) for complete transfer

• Antibody dilution:

  • Most PLXNA3 antibodies perform optimally at dilutions between 1:500 and 1:2000

  • Always validate optimal concentration with titration experiments

• Detection optimization:

  • Enhanced chemiluminescence (ECL) with longer exposure times may be necessary

  • Consider using HRP-conjugated secondary antibodies at 1:5000-1:10000 dilutions

Since PLXNA3 undergoes post-translational modifications including glycosylation , researchers may observe bands at slightly different molecular weights than predicted.

How can I optimize immunohistochemistry protocols for PLXNA3 detection in tissue sections?

For effective IHC detection of PLXNA3 in tissue sections, consider the following methodological approach:

• Fixation and antigen retrieval:

  • 4% paraformaldehyde fixation is generally recommended

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) for 20 minutes improves antibody access to the antigen

  • For membrane proteins like PLXNA3, additional permeabilization with 0.1% Triton X-100 may enhance antibody penetration

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from the same species as the secondary antibody

  • Incubate with primary PLXNA3 antibody overnight at 4°C

  • When using antibodies validated for IHC applications, follow manufacturer's recommended dilutions (typically 1:100-1:500)

• Detection and visualization:

  • For brightfield microscopy, DAB (3,3'-diaminobenzidine) substrate provides excellent contrast

  • For fluorescence applications, select secondary antibodies with minimal background in your tissue of interest

  • Include DAPI counterstain to visualize nuclei and cellular context

• Controls and validation:

  • Include tissue sections known to express PLXNA3 as positive controls

  • Always run parallel negative controls (primary antibody omission)

  • Consider using tissues from PLXNA3 knockout models if available

PLXNA3 expression is particularly enriched in neuronal tissues, making brain and spinal cord sections excellent positive controls when optimizing protocols .

How can I validate the specificity of a PLXNA3 antibody for my experimental system?

Thorough validation of PLXNA3 antibodies is critical for generating reliable research data. Implement these methodological approaches for comprehensive validation:

• Multiple detection methods:

  • Compare antibody performance across at least two detection methods (e.g., WB and IHC)

  • Confirm that the antibody detects proteins of expected molecular weight by Western blot

  • Verify expected cellular localization patterns using immunocytochemistry

• Genetic approaches:

  • Perform siRNA/shRNA knockdown of PLXNA3 and confirm reduction in signal

  • If possible, use CRISPR/Cas9-generated knockout cells as negative controls

  • For overexpression validation, compare antibody detection in cells transfected with PLXNA3 expression constructs versus empty vector controls

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide (if available)

  • Confirm signal reduction/elimination in parallel experiments

• Orthogonal validation:

  • Compare results with alternative antibodies recognizing different epitopes of PLXNA3

  • Consider mass spectrometry validation of immunoprecipitated proteins

• Cross-species validation:

  • If studying PLXNA3 across multiple species, verify sequence homology in the antibody's epitope region

  • For regions with high sequence conservation (like amino acids 950-1150 in human PLXNA3), antibodies may demonstrate cross-reactivity with orthologs

Documenting these validation experiments thoroughly provides critical support for your research findings and enhances reproducibility.

What experimental considerations are important when investigating PLXNA3's role in axon guidance and neuronal development?

When studying PLXNA3's function in axon guidance and neuronal development, implement these methodological approaches:

• Neurite outgrowth assays:

  • Use primary neuronal cultures or neuronal cell lines expressing PLXNA3

  • Apply semaphorin ligands (SEMA3A or SEMA3F) to assess growth cone collapse responses

  • Quantify morphological changes including neurite length, branching complexity, and growth cone area

• Co-immunoprecipitation studies:

  • Investigate PLXNA3 interactions with neuropilin co-receptors using IP-grade antibodies

  • Optimize lysis conditions to preserve membrane protein complexes

  • Include appropriate controls to confirm specificity of interactions

• Live imaging approaches:

  • Apply fluorescence microscopy to visualize PLXNA3-dependent cytoskeletal dynamics

  • Consider epitope-tagging strategies if direct antibody labeling affects protein function

• Functional blocking experiments:

  • Determine if antibodies targeting extracellular domains of PLXNA3 can functionally block semaphorin signaling

  • Compare results with genetic knockdown approaches to confirm specificity

• Model system considerations:

  • For developmental studies, consider the timing of PLXNA3 expression during neurogenesis

  • PLXNA3's role in dendrite spine morphology suggests importance in synaptogenesis and circuit formation

When interpreting results, consider the potential redundancy between plexin family members and compensatory mechanisms that may obscure phenotypes in single-gene perturbation experiments.

What are common pitfalls when using PLXNA3 antibodies and how can I address them?

When working with PLXNA3 antibodies, researchers commonly encounter these challenges and solutions:

• High molecular weight detection issues:

  • Problem: Incomplete transfer of large proteins (207.7 kDa) in Western blots

  • Solution: Use longer transfer times, wet transfer systems, and optimize gel percentage

• Multiple banding patterns:

  • Problem: Detection of multiple bands at unexpected molecular weights

  • Solution: Consider post-translational modifications (glycosylation), alternative splice variants, and proteolytic processing. Validate using appropriate controls and blocking peptides.

• Weak or inconsistent signal:

  • Problem: Low signal intensity despite expected high expression

  • Solution: Optimize antibody concentration, extend incubation times, and evaluate the need for enhanced detection systems

• Cross-reactivity concerns:

  • Problem: Non-specific binding to related plexin family members

  • Solution: Verify antibody specificity using knockout/knockdown controls and consider using antibodies targeting unique regions with lower homology to other plexins

• Immunohistochemistry background:

  • Problem: High background staining obscuring specific signals

  • Solution: Optimize blocking conditions, reduce antibody concentration, and include additional washing steps

For recalcitrant problems, consulting the technical support services of the antibody manufacturer can provide application-specific troubleshooting guidance.

How should I interpret variations in PLXNA3 expression patterns across different neural cell types and developmental stages?

When analyzing PLXNA3 expression data across different neural cell types and developmental stages:

• Developmental timing considerations:

  • Expression patterns may shift during developmental progression

  • Compare expression with known developmental markers to establish temporal context

  • Document precise developmental stages when reporting findings

• Cell-type specific expression analysis:

  • Use co-labeling with cell-type specific markers to confirm identity of PLXNA3-expressing cells

  • Consider single-cell approaches for heterogeneous populations

  • Interpret expression differences in the context of known functional roles in specific cell types

• Regional specificity interpretation:

  • Document anatomical context precisely when reporting expression patterns

  • Compare with known expression of semaphorin ligands to identify potential signaling relationships

  • Consider functional implications of regional expression differences

• Quantification approaches:

  • Employ standardized quantification methods (fluorescence intensity, cell counting)

  • Use appropriate statistical analyses for comparing expression levels

  • Include biological replicates to account for natural variation

• Integration with functional data:

  • Correlate expression patterns with known PLXNA3 functions in axon guidance and neuronal migration

  • Consider how expression variations might relate to region-specific guidance requirements

Remember that PLXNA3 expression often correlates with active neuronal migration and axon pathfinding processes, and may be downregulated following the completion of these developmental events .

How can I implement proximity ligation assays to study PLXNA3 interactions with semaphorins and neuropilins?

Proximity Ligation Assay (PLA) offers a powerful approach for visualizing protein-protein interactions between PLXNA3 and its binding partners in situ:

• Experimental design considerations:

  • Select antibodies raised in different host species targeting PLXNA3 and its potential binding partners

  • Verify that antibodies recognize native (non-denatured) epitopes

  • Include appropriate positive and negative interaction controls

• Protocol optimization:

  • Fix cells using methods that preserve membrane protein topology

  • Optimize permeabilization to allow antibody access while maintaining protein complexes

  • Follow manufacturer's protocol for PLA-specific reagents (e.g., Duolink)

• Data analysis approaches:

  • Quantify PLA signals per cell using appropriate image analysis software

  • Compare signal intensity across experimental conditions

  • Consider co-labeling with subcellular markers to determine compartmentalization of interactions

• Biological applications:

  • Investigate dynamic interactions between PLXNA3 and semaphorins following ligand stimulation

  • Examine how PLXNA3-neuropilin interactions change during neuronal development

  • Assess how disease-relevant mutations affect interaction patterns

PLA can reveal transient or weak interactions that might be difficult to detect using conventional co-immunoprecipitation approaches, providing spatial information about where these interactions occur within the cell.

What considerations are important when using PLXNA3 antibodies for studying its role in pathological conditions?

When investigating PLXNA3 in disease contexts, consider these methodological approaches:

• Tissue selection and processing:

  • For neurodevelopmental disorders, select appropriate developmental timepoints

  • In neurodegenerative conditions, consider regional variability in pathology

  • Optimize tissue processing to preserve both protein integrity and anatomical context

• Quantitative analysis approaches:

  • Implement blinded quantification strategies

  • Use appropriate normalization controls

  • Consider multiple methodologies (protein levels, mRNA expression) for comprehensive assessment

• Comparison with pathological markers:

  • Co-label with disease-specific markers to establish correlations

  • Document spatial relationships between PLXNA3 expression and pathological features

  • Consider temporal progression of changes relative to disease onset

• Functional implications:

  • Design experiments to determine whether changes in PLXNA3 expression are causative or consequential

  • Consider how altered PLXNA3 signaling might contribute to observed pathology

  • Explore potential as a biomarker or therapeutic target

• Technical considerations for pathological specimens:

  • Pathological tissues may require modified protocols for optimal antibody performance

  • Include appropriate tissue-matched controls

  • Document processing variables that might affect antibody binding

While PLXNA3's primary roles have been established in neurodevelopment, emerging evidence suggests potential involvement in neurological disorders, cancer progression, and regenerative processes following injury .